
    
      Part A of the study will evaluate the safety and tolerability, PK, and PD of single ascending
      doses of VX-509.

      Part B will evaluate the safety and tolerability, PK, and PD of multiple ascending doses of
      VX-509 administered for 14 days.

      A total of 72 subjects will be enrolled: 36 subjects in Part A and 36 subjects in Part B.
    
  